M0248 Insurance Policy Changes

HCPCS M0248 is officially defined as "Intravenous infusion, sotrovimab, includes infusion and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency." HCPCS M0248 is referenced in 2 tracked payer policy changes from Michigan Medicaid - MDHHS and Blue Cross Blue Shield of Rhode Island. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for HCPCS M0248 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.